Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence in Greater China

 Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence in Greater China

Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence in Greater China

Shots:

  • Samsung Biologics entered into an agreement with APRINOIA Therapeutics to develop an anti-tau mAb for treating primary and secondary tauopathies, including PSP and AD
  • APRINOIA will utilize its Ab platform for selecting the candidate and targets specific pathological tau aggregates with novel conformation-dependent epitopes with an aim to slow down disease progression
  • The collaboration encompasses product’s development phase from cell line development, process development, cGMP manufacturing to IND filing while with the collaboration Samsung Biologics has reconfirmed its position as a global leading CMO, CDO, and CRO partner

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Samsung Biologics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post